Serious adverse events (at 54 weeks) · patients with Crohn's disease (mixed disease activity population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 54 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Clinical relapse · Participants with Crohn's disease in remission
Infliximab combined with purine analogues probably leads to lower clinical relapse (at 48 weeks, CDAI of 150 or greater together with… compared with purine analogues (moderate certainty).
1 finding from 1 review
Loss of clinical response · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Participants with Crohn's disease in remission
It is very uncertain whether infliximab combined with purine analogues changes withdrawal due to adverse events (at 48 weeks) compared with purine analogues (very low certainty).
1 finding from 1 review
Serious adverse events (at 48 weeks to 2 years) · Participants with Crohn's disease in remission
It is very uncertain whether infliximab combined with purine analogues changes serious adverse events (at 48 weeks to 2 years) compared with purine analogues (very low certainty).
1 finding from 1 review
Clinical relapse · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (dichotomous) · active EoE patients
Corticosteroids may leads to higher clinical improvement (dichotomous) compared with placebo (low certainty).
1 finding from 1 review
Histological improvement (dichotomous) · inactive EoE patients
Corticosteroids probably leads to higher histological improvement (dichotomous) compared with placebo (moderate certainty).
1 finding from 1 review
Clinical improvement (continuous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement (dichotomous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement (continuous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (dichotomous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (continuous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · inactive EoE patients
It is very uncertain whether leukotriene receptor antagonist changes withdrawals due to adverse events at 26 weeks compared with placebo (very low certainty).
1 finding from 1 review
Clinical improvement (dichotomous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement (dichotomous) · active EoE pediatric patients
It is very uncertain whether mepolizumab 10 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 0.55 mg/kg (very low certainty).
1 finding from 1 review
Histological improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement (continuous) · inactive EoE patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found